RNS Number:1003S
BTG PLC
14 November 2003



14 November 2003 - for immediate release



BTG plc: Statement on Varisolve(R) US Phase II safety study



BTG plc (LSE: BGC), the global technology commercialisation company, today
announced that it has been informed verbally by the US Food & Drug
Administration (FDA) of a decision to place on clinical hold a Phase II safety
study of Varisolve(R), a new treatment for varicose veins being developed by
Provensis, BTG's subsidiary.



FDA has indicated it will write to Provensis describing the reasons for placing
the study on clinical hold.  BTG will make a further announcement after
receiving the FDA's letter and assessing the impact on the further clinical
development of Varisolve(R).



Ends



For further information contact:


BTG
Andy Burrows, Director of Investor Relations
+44 (0)20 7575 1741
07990 530605




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

RESNKQKNPBDDQDD